Mather Group, Llc. Biogen Inc. Transaction History

Mather Group, Llc.

$7.74 Billion
Q3 2024

A detailed history of Mather Group, Llc. transactions in Biogen Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 300 shares of BIIB stock, worth $52,137. This represents 0.0% of its overall portfolio holdings.

Number of Shares

300

Previous 1,223 75.47%

Holding current value

$52,137

Previous $283,000 79.51%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 07, 2024	SELL	$189.07 - $236.8 $174,511 - $218,566	-923 Reduced 75.47%	300 $58,000
Q2 2024 Jul 08, 2024	BUY	$190.52 - $236.72 $34,484 - $42,846	181 Added 17.37%	1,223 $283,000
Q1 2024 Apr 08, 2024	SELL	$212.02 - $267.71 $1,272 - $1,606	-6 Reduced 0.57%	1,042 $224,000
Q4 2023 Feb 05, 2024	SELL	$222.59 - $267.94 $25,597 - $30,813	-115 Reduced 9.89%	1,048 $271,000
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $120,064 - $135,511	-474 Reduced 28.96%	1,163 $298,000
Q2 2023 Aug 08, 2023	BUY	$275.25 - $318.06 $450,584 - $520,664	1,637 New	1,637 $466,000
Q4 2021 Feb 15, 2022	SELL	$223.92 - $287.77 $161,446 - $207,482	-721 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$282.99 - $369.05 $19,243 - $25,095	68 Added 10.41%	721 $204,000
Q2 2021 Aug 13, 2021	SELL	$259.0 - $414.71 $21,238 - $34,006	-82 Reduced 11.16%	653 $226,000
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $178,568 - $209,203	735 New	735 $206,000
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $227,518 - $342,471	-963 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$264.77 - $305.71 $114,645 - $132,372	-433 Reduced 31.02%	963 $273,000
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $361,089 - $478,199	1,396 New	1,396 $373,000

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mather Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Mather Group, Llc. with notifications on news.

Account